Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. This disparity of outcomes merited further studies because interactions between these modalities de...

The long-heralded potential of targeted cancer treatment using monoclonal antibodies is finally being realized. Several antibodies are already used in the oncology clinic and many others are undergoing preclinical evaluation. In addition to the development of unconjugated antibodies, there is intense interest in the potential clinical use of antibodies as vehicles for targeting cytotoxic agents...

Recombinant human interleukin 1 (IL-1) administered i.p. to tumor-bearing hamsters results in a dose-dependent 2- to 5-fold increase in total peripheral white blood cells. These levels remain elevated for 2 to 3 wk and then decline to base-line levels. Pretreatment of animals with similar doses of IL-1 prevents radioimmunotherapy-induced destruction of the radiosensitive hematopoietic system. F...

PURPOSE Monoclonal antibodies and tyrosine kinase inhibitors specific for the epidermal growth factor receptor (EGFR) have been shown to enhance the effect of external beam radiation on EGFR-positive tumors. The effect of EGFR signaling abrogation by EGFR tyrosine kinase inhibitor on the efficacy of radioimmunotherapy has not been reported previously. This study investigated the effect of EGFR ...

the principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against tumors in both humans and animals. this advanced technology of hybridoma production provided the necessary skills to efficiently produce highly specific monoclonal antibodies (mab). radioactively-tagged antibodies which are applied in radioimmunotherapy (rit), can target adjacen...